REFERENCES
1. Yoshizumi T, Harimoto N, Itoh S, et al. Living donor liver transplantation for hepatocellular carcinoma within milan criteria in the present era. Anticancer Res 2016;36:439-45.
2. Chen CL, Kabiling CS, Concejero AM. Why does living donor liver transplantation flourish in Asia? Nat Rev Gastroenterol Hepatol 2013;10:746-51.
4. Lo CM, Fan ST, Liu CL, et al. Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg 1997;226:261-9; discussion 269-70.
5. Liver transplant centre. (2019). Available from: https://www8.ha.org.hk/qmh/patient_and_visitor/medical_services/liver_transplant_centre.aspx [Last accessed on 7 Jan 2022].
6. Blok JJ, de Boer JD, Putter H, et al. Eurotransplant Liver Intestine Advisory Committee. The center effect in liver transplantation in the Eurotransplant region: a retrospective database analysis. Transpl Int 2018;31:610-9.
7. Macomber CW, Shaw JJ, Santry H, et al. Centre volume and resource consumption in liver transplantation. HPB (Oxford) 2012;14:554-9.
8. Chan SC, Lo CM, Ng KK, Ng IO, Yong BH, Fan ST. Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein. Liver Transpl 2011;17:115-21.
9. Fan ST, Lo CM, Liu CL. Technical refinement in adult-to-adult living donor liver transplantation using right lobe graft. Ann Surg 2000;231:126-31.
10. Lo CM, Fan ST, Liu CL, Wong J. Hepatic venoplasty in living-donor liver transplantation using right lobe graft with middle hepatic vein. Transplantation 2003;75:358-60.
11. Fan ST, Wei WI, Yong BH, et al. Living donor liver transplantation. World Scientific; 2011.
12. She WH, Chok KS, Fung JY, Chan AC, Lo CM. Outcomes of right-lobe and left-lobe living-donor liver transplantations using small-for-size grafts. World J Gastroenterol 2017;23:4270-7.
13. Lo CM, Fan ST, Liu CL, et al. Minimum graft size for successful living donor liver transplantation. Transplantation 1999;68:1112-6.
14. Kawasaki S, Makuuchi M, Matsunami H, et al. Living related liver transplantation in adults. Ann Surg 1998;227:269-74.
15. de Villa VH, Chen CL, Chen YS, et al. Right lobe living donor liver transplantation-addressing the middle hepatic vein controversy. Ann Surg 2003;238:275-82.
16. Ma KW, Wong KHC, Chan ACY, et al. Impact of small-for-size liver grafts on medium-term and long-term graft survival in living donor liver transplantation: a meta-analysis. World J Gastroenterol 2019;25:5559-68.
17. Man K, Fan ST, Lo CM, et al. Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. Ann Surg 2003;237:256-64.
18. Ito T, Kiuchi T, Yamamoto H, et al. Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications. Transplantation 2003;75:1313-7.
19. Wei WI, Lam LK, Ng RW, et al. Microvascular reconstruction of the hepatic artery in live donor liver transplantation: experience across a decade. Arch Surg 2004;139:304-7.
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-13.
21. Arbuthnot P, Kew M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 2001;82:77-100.
22. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
23. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
24. Ma KW, Chok KSH, Fung JYY, Lo CM. Liver transplantation for hepatitis B virus-related hepatocellular carcinoma in Hong Kong. J Clin Transl Hepatol 2018;6:283-8.
25. Lin C, Elsarawy AMAA, Chen C. Living donor liver transplantation for hepatocellular carcinoma. In: Abdeldayem HM, editor. Updates in Liver Cancer. InTech; 2017.
26. Mailey B, Artinyan A, Khalili J, et al. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011;146:26-33.
27. Todo S, Furukawa H, Tada M. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007;13:S48-S54.
28. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008;85:1726-32.
29. Todo S, Furukawa H. Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-9; discussion 459-61.
30. Ng KK, Lo CM, Chan SC, Chok KS, Cheung TT, Fan ST. Liver transplantation for hepatocellular carcinoma: the Hong Kong experience. J Hepatobiliary Pancreat Sci 2010;17:548-54.
31. Bhangui P, Allard MA, Vibert E, et al. Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes? Ann Surg 2016;264:155-63.
32. Broelsch CE, Whitington PF, Emond JC, et al. Liver transplantation in children from living related donors. Surgical techniques and results. Ann Surg 1991;214:428-37; discussion 437-9.
33. Hatano E, Terajima H, Yabe S, et al. Hepatic artery thrombosis in living related liver transplantation. Transplantation 1997;64:1443-6.
34. Sakamoto Y, Harihara Y, Nakatsuka T, et al. Rescue of liver grafts from hepatic artery occlusion in living-related liver transplantation. Br J Surg 1999;86:886-9.
35. Goldstein MJ, Salame E, Kapur S, et al. Analysis of failure in living donor liver transplantation: differential outcomes in children and adults. World J Surg 2003;27:356-64.
36. Millis JM, Cronin DC, Brady LM, et al. Primary living-donor liver transplantation at the University of Chicago: technical aspects of the first 104 recipients. Ann Surg 2000;232:104-11.
37. Uchiyama H, Hashimoto K, Hiroshige S, et al. Hepatic artery reconstruction in living-donor liver transplantation: a review of its techniques and complications. Surgery 2002;131:S200-4.
38. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006;6:1578-85.
39. Randhawa PS, Starzl TE, Demetris AJ. Tacrolimus (FK506)-associated renal pathology. Adv Anat Pathol 1997;4:265-76.
40. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005;11:497-503.
41. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
42. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
43. Diekmann F, Campistol JM. Practical considerations for the use of mTOR inhibitors. Transplant Res 2015;4:5.
44. Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18:62-9.
46. McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001;7:701-8.
47. Fung J. Management of chronic hepatitis B before and after liver transplantation. World J Hepatol 2015;7:1421-6.
48. Lo CM, Cheung ST, Lai CL, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001;233:276-81.
49. Fung J, Chan SC, Cheung C, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013;108:942-8.
50. Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years. Hepatology 2017;66:1036-44.
52. Nguyen KT, Marsh JW, Tsung A, Steel JJ, Gamblin TC, Geller DA. Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal. Arch Surg 2011;146:348-56.
53. Simillis C, Constantinides VA, Tekkis PP, Darzi A, Lovegrove R, Jiao L, Antoniou A. Laparoscopic versus open hepatic resections for benign and malignant neoplasms-a meta-analysis. Surgery 2007;141:203-11.
54. Croome KP, Yamashita MH. Laparoscopic vs open hepatic resection for benign and malignant tumors: an updated meta-analysis. Arch Surg 2010;145:1109-18.
55. Zhou YM, Shao WY, Zhao YF, Xu DH, Li B. Meta-analysis of laparoscopic versus open resection for hepatocellular carcinoma. Dig Dis Sci 2011;56:1937-43.
56. Mirnezami R, Mirnezami AH, Chandrakumaran K, et al. Short- and long-term outcomes after laparoscopic and open hepatic resection: systematic review and meta-analysis. HPB (Oxford) 2011;13:295-308.
57. Mizuguchi T, Kawamoto M, Meguro M, et al. Laparoscopic hepatectomy: a systematic review, meta-analysis, and power analysis. Surg Today 2011;41:39-47.
58. Li N, Wu YR, Wu B, Lu MQ. Surgical and oncologic outcomes following laparoscopic versus open liver resection for hepatocellular carcinoma: a meta-analysis. Hepatol Res 2012;42:51-9.
59. Kim KH, Jung DH, Park KM, et al. Comparison of open and laparoscopic live donor left lateral sectionectomy. Br J Surg 2011;98:1302-8.
60. Kim SH, Lee SD, Kim YK, Park SJ. Pushing the frontiers of living donor right hepatectomy. World J Gastroenterol 2014;20:18061-9.
61. Kim KH, Kang SH, Jung DH, et al. Initial outcomes of pure laparoscopic living donor right hepatectomy in an experienced adult living donor liver transplant center. Transplantation 2017;101:1106-10.
62. Wakabayashi G, Nitta H, Takahara T, Shimazu M, Kitajima M, Sasaki A. Standardization of basic skills for laparoscopic liver surgery towards laparoscopic donor hepatectomy. J Hepatobiliary Pancreat Surg 2009;16:439-44.
63. Kim JH, Ryu DH, Jang LC, Choi JW. Lateral approach liver hanging maneuver in laparoscopic anatomical liver resections. Surg Endosc 2016;30:3611-7.
65. Ishizawa T, Saiura A, Kokudo N. Clinical application of indocyanine green-fluorescence imaging during hepatectomy. Hepatobiliary Surg Nutr 2016;5:322-8.
66. Giulianotti PC, Coratti A, Angelini M, et al. Robotics in general surgery: personal experience in a large community hospital. Arch Surg 2003;138:777-84.
67. Choi GH, Choi SH, Kim SH, et al. Robotic liver resection: technique and results of 30 consecutive procedures. Surg Endosc 2012;26:2247-58.
68. Choi SH, Choi GH, Han DH, Choi JS. Laparoscopic liver resection using a rubber band retraction technique: usefulness and perioperative outcome in 100 consecutive cases. Surg Endosc 2015;29:387-97.
69. Park JI, Kim KH, Kim HJ, et al. Highlights of the third expert forum of Asia-pacific laparoscopic hepatectomy; endoscopic and laparoscopic surgeons of Asia (ELSA) visionary summit 2017. Ann Hepatobiliary Pancreat Surg 2018;22:1-10.
70. Chen PD, Wu CY, Wu YM. Use of robotics in liver donor right hepatectomy. Hepatobiliary Surg Nutr 2017;6:292-6.
71. Chen PD, Wu CY, Hu RH, et al. Robotic liver donor right hepatectomy: a pure, minimally invasive approach. Liver Transpl 2016;22:1509-18.
72. Zhu P, Liao W, Ding zy, et al. learning curve in robot-assisted laparoscopic liver resection. J Gastrointest Surg 2019;23:1778-87.
73. Saito Y, Yamada S, Imura S, et al. A learning curve for laparoscopic liver resection: an effective training system and standardization of technique. Transl Gastroenterol Hepatol 2018;3:45.
74. Sapisochin G, Goldaracena N, Laurence JM, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology 2016;64:2077-88.
75. Suzuki M, Shiraha H, Fujikawa T, et al. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005;280:6409-15.
76. Fujikawa T, Shiraha H, Ueda N, et al. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem 2007;282:8741-8.
77. Tanaka Y, Kashiwagi T, Tsutsumi H, et al. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma. Hepatogastroenterology 1999;46:2464-8.
78. Ikoma J, Kaito M, Ishihara T, et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002;49:235-8.
79. Chaiteerakij R, Zhang X, Addissie BD, et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2015;21:599-606.
80. Funaki NO, Tanaka J, Seto SI, Kasamatsu T, Kaido T, Imamura M. Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology 1997;25:564-8.
81. Kobayashi M, Hosaka T, Ikeda K, et al. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011;41:1036-45.
82. Limaye AR, Clark V, Soldevila-Pico C, et al. Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res 2013;43:757-64.
83. Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250:141-51.
84. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007;13:1637-44.
